Back to Search Start Over

Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence

Authors :
Shao-Lai Zhou
Zheng-Jun Zhou
Cheng-Li Song
Hao-Yang Xin
Zhi-Qiang Hu
Chu-Bin Luo
Yi-Jie Luo
Jia Li
Zhi Dai
Xin-Rong Yang
Ying-Hong Shi
Zheng Wang
Xiao-Wu Huang
Jia Fan
Jian Zhou
Source :
Signal Transduction and Targeted Therapy, Vol 7, Iss 1, Pp 1-17 (2022)
Publication Year :
2022
Publisher :
Nature Publishing Group, 2022.

Abstract

Abstract Patients with hepatocellular carcinoma (HCC) have poor long-term survival following curative resection because of the high rate of tumor early recurrence. Little is known about the trajectory of genomic evolution from primary to early-recurrent HCC. In this study, we performed whole-genome sequencing (WGS) on 40 pairs of primary and early-recurrent hepatitis B virus (HBV)-related HCC tumors from patients who received curative resection, and from four patients whose primary and recurrent tumor were extensively sampled. We identified two recurrence patterns: de novo recurrence (18/40), which developed genetically independently of the primary tumor and carried different HCC drivers, and ancestral recurrence (22/40), which was clonally related to the primary tumor and progressed more rapidly than de novo recurrence. We found that the recurrence location was predictive of the recurrence pattern: distant recurrence tended to display the de novo pattern, whereas local recurrence tended to display the ancestral pattern. We then uncovered the evolutionary trajectories based on the subclonal architecture, driver-gene mutations, and mutational processes observed in the primary and recurrent tumors. Multi-region WGS demonstrated spatiotemporal heterogeneity and polyclonal, monophyletic dissemination in HCC ancestral recurrence. In addition, we identified recurrence-specific mutations and copy-number gains in BCL9, leading to WNT/β-catenin signaling activation and an immune-excluded tumor microenvironment, which suggests that BCL9 might serve as a new therapeutic target for recurrent HCC. Collectively, our results allow us to view with unprecedented clarity the genomic evolution during HBV-related HCC early recurrence, providing an important molecular foundation for enhanced understanding of HCC with implications for personalized therapy to improve patient survival.

Details

Language :
English
ISSN :
20593635
Volume :
7
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Signal Transduction and Targeted Therapy
Publication Type :
Academic Journal
Accession number :
edsdoj.f0a7af90e44446f1b0b15156fc8c796b
Document Type :
article
Full Text :
https://doi.org/10.1038/s41392-021-00838-3